Dr. Eric C. Mcgary, MD
Hematology & Oncology (Hematology & Oncology Physician)
6041 Cadillac Ave
Los Angeles, CA 90034
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Tulane University School of Medicine (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 11
Licensed in California since 1998, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Tulane University School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license A66028 (first issued 1998; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Kaiser Foundation Hospital - West La Los Angeles, CA
Medical groups
- Southern California Permanente Medical Group (11,293 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 11
- Services billed
- 70
- Patients’ average age
- 70
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Xtandi (enzalutamide) | 104 |
| Abiraterone Acetate | 95 |
| Prednisone Other prescribers in Los Angeles, CA | 57 |
| Tagrisso (osimertinib mesylate) | 57 |
| Brukinsa (zanubrutinib) | 47 |
| Dexamethasone Other prescribers in Los Angeles, CA | 37 |
| Nivestym (filgrastim-aafi) | 29 |
| Imbruvica (ibrutinib) | 20 |
| Prochlorperazine Maleate Other prescribers in Los Angeles, CA | 18 |
| Bosulif (bosutinib) | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $272,639 in research payments for these studies, mostly to the institutions running them.
- A phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non …
AstraZeneca Pharmaceuticals LP - A phase 3, multicenter, double-blind, placebo-controlled study assessing the efficacy and safety of olomorasib in combination with standard of care immunotherapy in participants with resected or unresectable kras G12C…
Eli Lilly and Company - Early Stage to Locally Advanced Non Small Cell Lung Cancer platform stage 3 unresectable
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.